Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941025 · ClinicalTrials.gov registry record
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
A clinical trial of Pregnancy and Pregnancy Complications, sponsored by Chiesi Farmaceutici S.p.A..
- Recruiting
- Registry status
- 10
- Enrollment target
- 5
- Study locations
NCT06941025 is a study of Pregnancy and Pregnancy Complications that is actively recruiting participants, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 10 participants, below the 873-participant average among 191 other Pregnancy trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT06941025, a study of Pregnancy and Pregnancy Complications, is actively recruiting participants, sponsored by Chiesi Farmaceutici S.p.A..
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this observational registry is to evaluate the safety and outcomes of pregnancy and lactation in women with Fabry disease who are exposed to pegunigalsidase alfa within 30 days prior to conception and/or during pregnancy and lactation. The main objectives are to: * Assess pregnancy outcomes, including maternal and infant health. * Evaluate the occurrence of congenital malformations and other neonatal outcomes. This is a global, decentralized, single-arm, prospective and retrospective registry planned to enroll participants over a 10-year period. Eligible patients may be enrolled by their physician or may self-enroll, where permitted by local regulations. Data will be collected through a secure web-based platform, allowing patients and physicians to enter information via electronic case report forms (eCRFs). Pregnancy and clinical outcomes will be documented throughout pregnancy and up to 12 months post-birth. Data from self-enrolled patients will be confirmed by their primary care or attending physician. This registry is observational and does not impact clinical care or treatment decisions.
Conditions Studied
Interventions
- OTHER Not applicable- observational study
Study Locations (5)
Other
- No physical study sites - Decentralized, web-based registry - Berlin
- No physical study sites - Decentralized, web-based registry - Rome
- No physical study sites - Decentralized, web-based registry - Madrid
- No physical study sites - Decentralized, web-based registry - London
District of Columbia
- No physical study sites - Decentralized, web-based registry - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-05-23 |
| Est. Completion | 2034-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06941025
The ClinicalTrials.gov registry entry for NCT06941025 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 873-participant average among 191 other Pregnancy trials with a reported enrollment target (99% lower). The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which Not applicable- observational study is the first listed.
NCT06941025 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06941025 about?
NCT06941025 is a clinical study titled "Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding". The goal of this observational registry is to evaluate the safety and outcomes of pregnancy and lactation in women with Fabry disease who are exposed to pegunigalsidase alfa within 30 days prior to conception and/or during pregnancy and lactation. The main objectives are to: * Assess pregnancy out...
What is the current status of trial NCT06941025?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2025-05-23. Estimated completion is 2034-12.
What conditions does trial NCT06941025 study?
This clinical trial studies the following conditions: Pregnancy, Pregnancy Complications, Fabry Disease.
What interventions are being tested in trial NCT06941025?
The interventions under investigation include: Not applicable- observational study (OTHER).
Who is sponsoring clinical trial NCT06941025?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941025 being conducted?
This trial has 5 study locations across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
RECRUITING
-
Cocooned Moms Study
RECRUITING · NA
-
Retinal Vascular Changes During Pregnancy
RECRUITING
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.